Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Travere Therapeutics Inc (NQ: TVTX ) 13.49 +0.89 (+7.06%) Streaming Delayed Price Updated: 3:44 PM EDT, Sep 13, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Travere Therapeutics Inc < Previous 1 2 3 4 5 6 7 8 9 10 Next > Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 12, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference September 10, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday September 09, 2024 Via Benzinga Analyst Ratings For Travere Therapeutics September 06, 2024 Via Benzinga Expert Ratings For Travere Therapeutics August 02, 2024 Via Benzinga Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts May 07, 2024 Via Benzinga Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know April 17, 2024 Via Benzinga Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday September 06, 2024 Via Benzinga Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease September 06, 2024 The company previously had an accelerated approval for its IgA nephropathy treatment. Via Investor's Business Daily NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday September 06, 2024 Via Benzinga Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy September 05, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024 August 22, 2024 Posters to be presented highlight clinical study designs investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences August 06, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024 August 02, 2024 Via AB Newswire Topics Intellectual Property Exposures Intellectual Property Travere Therapeutics Reports Second Quarter 2024 Financial Results August 01, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal July 27, 2024 Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus... Via Talk Markets Travere Therapeutics to Report Second Quarter 2024 Financial Results July 25, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire 10 Health Care Stocks Whale Activity In Today's Session July 10, 2024 Via Benzinga Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday July 09, 2024 Via Benzinga Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference July 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 11, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 15, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress May 09, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences May 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire TVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024 May 06, 2024 TVTX stock results show that Travere Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Via InvestorPlace Travere Therapeutics Reports First Quarter 2024 Financial Results May 06, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Report First Quarter 2024 Financial Results April 29, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy April 24, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International April 04, 2024 Posters to be presented highlighting research investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association April 03, 2024 Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere’s leadership and commitment to innovation in rare kidney disease (RKD) From Travere Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.